Remove Dermatology Remove Innovations Remove Safety
article thumbnail

Cosmetic Dermatology in the Digital Age: How to Harness Technology and Uphold Safety and Ethics

The Dermatology Digest

Artificial intelligence (AI), augmented reality, social media, telehealth, and other emerging technologies are changing the way that healthcare is delivered, and cosmetic dermatology is no exception. She believes some conditions, consultations, and procedures require in-person appointments to ensure safety and accuracy.

Ethics 74
article thumbnail

Icotrokinra Shows Efficacy and Safety in Adolescents With Moderate to Severe PsO

The Dermatology Digest

These data were presented at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting in Buenos Aires, Argentina. ” Icotrokinra demonstrated a favorable safety profile. In the study, 84.1% achieved a Psoriasis Area and Severity Index (PASI) 90 response, compared to 27.3% and Janssen Biotech, Inc.,

Safety 36
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Monica K. Li, MD: Global Innovations, Integration with Other Modalities, and Future Trends in Microneedling

Dermatology Times

Li discusses microneedling innovations, global techniques, safety, and future trends in dermatology, including integration with RF and PRP.

article thumbnail

U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN

The Dermatology Digest

It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. The post U.S

article thumbnail

This Week’s Hottest Drops, Launches, and Collabs

The Dermatology Digest

We are confident this innovation will redefine how we think about skin health.” ” A double-blinded, randomized, placebo-controlled trial evaluated the safety and efficacy of BioRewind in 104 patients over 12-weeks.

article thumbnail

Championing Patient and Consumer Safety in Dermatology

Dermatology Times

Dermatology Times' Editor in Chief Christopher Bunick, MD, PhD, discusses patient safety in the wake of AAD 2025, focusing on BPO recalls, corticosteroid risks, and JAK inhibitor innovations.

Safety 36
article thumbnail

Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO

The Dermatology Digest

improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest.